National Health (April 2020 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2020
National Health Act 1953
I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 99ACF(3AA) of the National Health Act 1953.
Dated 30 March 2020
THEA DANIEL
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health
1 Name of Determination
This instrument is the National Health (April 2020 First New Brand statutory price reduction) (Exercise of Ministerial discretion) Determination 2020.
2 Commencement
This instrument commences on 1 April 2020.
3 Definition
Note: A number of expressions used in this instrument are defined in Part VII the Act,
In this instrument:
Act means the National Health Act 1953.
4 Authority
This instrument is made under subsection 99ACF(3AA) of the Act.
5 Brand of pharmaceutical item not subject to a price reduction
I determine under subsection 99ACF(3AA) of the Act that, for the purposes of subsection 99ACF(2AB), the approved ex-manufacturer price that comes into force on 1 April 2020 of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 1 is to be worked out using a reduction of zero %.
Schedule 1— Brands of pharmaceutical items with approved ex-manufacturer price not reduced
Column 1 | Column 2 | |||
Item | Brand of Pharmaceutical Item | |||
| Drug | Form | Manner of administration | Brand |
1 | Levodopa with carbidopa | Tablet (modified release) 200 mg-50 mg (as monohydrate) | Oral | Sinemet CR
|
2 | Levodopa with carbidopa | Tablet (prolonged release) 200 mg-50 mg | Oral | Sinemet CR Prolonged-Release Tablets
|